Collectively, evidence highlights PRMT5 inhibitors as promising therapeutic targets for bone tumors, particularly in tumor subtypes exhibiting high dependency on PRMT5 and harboring specific splicing factor mutations. This evidence concerns the gene PRMT5 and neoplasm.